Coronary and cardiovascular risk estimation for primary prevention: Validation of a new Sheffield table in the 1995 Scottish health survey population

BMJ

Volumn 320, Issue 7236, 2000, Pages 671-676

  Wallis, Erica J ^a   Ramsay, Lawrence E ^a   Haq, Iftikhar ui ^a   Ghahramani, Parviz ^a   Jackson, Peter R ^a   Yeo, Karen Rowland ^a   Yeo, wilfred w ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; ARTICLE; BORDERLINE HYPERTENSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; FEMALE; GENERAL PRACTICE; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MALE; NORMAL HUMAN; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

ADULT; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CONFIDENCE INTERVALS; CORONARY DISEASE; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RISK ASSESSMENT; SCOTLAND; SENSITIVITY AND SPECIFICITY;

EID: 0034635863     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.320.7236.671     Document Type: Article

References (24)

1. Haq IU, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci 1996; 91: 399–413.
2. Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU, Yeo WW, et al. Cost-effectiveness of HMG CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment Heart 1999; 82: 325–332.
3. Core Services Committee, Ministry of Health. Ministry of Health guidelines for the management of mildly raised blood pressure in New Zealand. Wellington: Ministry of Health, 1995.
4. Ramsay LE, Wallis EJ, Yeo WW, Jackson PR. The rationale for differing national recommendations for the treatment of hypertension. Am J Hypertens 1998; 11: 79–88S.
5. Boissel JP. Individualizing aspirin therapy for prevention of cardiovascular events. JAMA 1998; 280: 1949–1950.
6. Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R on behalf of the British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society and endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(suppl 2): S1–29.
7. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319: 630–635.
8. Anderson KM, Odel PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293–298.
9. Grover SA, Coupal L, Hu X-P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995; 274: 801–806.
10. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998; 19: 1434–1503.
11. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.
12. Hingorani AD, Vallance P. A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ 1999; 318: 101–105.
13. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346: 1467–1471.
14. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996; 348: 387–388.
15. Haq IU, Ramsay LE, Jackson PR, Wallis EJ. Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods. Q J Med 1999; 92: 379–385.
16. Joint Health Surveys Unit of Social and Community Planning Research and University College London. Scottish health survey. Colchester: University of Essex, 1995 (computer file, 2nd ed). (The Data Archive (distributor), 30 November 1998. SN;3807)
17. Downs GR, Clearfield M, Weiss S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–1622.
18. Standing Medical Advisory Committee. The use of statins. London: Department of Health, 1997. (11061 HCD Aug 97(04))
19. Collins R, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD, ed. Textbook of hypertension. Oxford: Blackwell Scientific, 1992: 1156–1164.
20. Sytkowski PA, D'Agostino RB, Huse DM, Russell MW, Hartz SC. New coronary risk functions for pharmacologically treated hypertensives: the Framingham heart study. Circulation 1997; 96(suppl I): 437.
21. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, the National High Blood Pressure Education Program Coordinating Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1998; 157: 2413–2446.
22. National Cholesterol Education Programme. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994; 89: 1333–1345.
23. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183.
24. Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999; 81: 40–46.